Abstract
Prediction of post-progression survival in patients with advanced hepatocellular carcinoma treated with sorafenib by using time-dependent changes in clinical characteristics
Highlights
Hepatocellular carcinoma (HCC) is the third common cause of cancer-related deaths worldwide
We reviewed data that were prospectively collected from 171 consecutive patients who received sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals, West Haven, computed tomography (CT), USA) for the treatment of advanced HCC at the Department of Hepato-Biliary-Pancreatic Surgery at the National Hospital Organization Kyushu Medical Center between June 2009 and July 2016
HCC was diagnosed based on the results of a pathological examination or a combination of specific radiologic findings obtained via contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) according to the criteria of the American Association for the Study of Liver Diseases[2]
Summary
Hepatocellular carcinoma (HCC) is the third common cause of cancer-related deaths worldwide. It has been shown to prolong both, progression-free survival and overall survival (OS) in patients with advanced HCC[4,5]. Since the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial showed the efficacy of sorafenib for prolonging survival in HCC patients almost 10 years ago[4], all phase 3 trials of novel systemic drugs have failed to improve outcomes over sorafenib, both, as first-line[6,7,8,9,10] and second-line treatments (following sorafenib)[10,11,12]. Since tumor progression is a dynamic process, it may be difficult to identify predictors for survival by analyzing clinical characteristic at one static data point. Using dynamic data might help clarify the predictors of survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
